Summit Securities Group’s GSK GSK Stock Holding History

Summit Securities Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,280	Closed	-$70K	–	1023
2022 Q2	$70K	Buy	1,280 +320	+33%	+$17.7K	0.01%	471
2022 Q1	$52K	Buy	+960	New	+$52.1K	0.01%	601
2021 Q2	–	Sell	-56	Closed	-$250K	–	758
2021 Q1	$250K	Sell	56 -142	-72%	-$6.45K	0.03%	482
2020 Q4	$913K	Buy	198 +20	+11%	+$919	0.08%	245
2020 Q3	$836K	Buy	178 +83	+87%	+$4.16K	0.09%	171
2020 Q2	$485K	Buy	95 +15	+19%	+$770	0.06%	238
2020 Q1	$379K	Sell	80 -174	-69%	-$9.28K	0.07%	181
2019 Q4	$1.49M	Buy	254 +191	+303%	+$10.6K	0.11%	171
2019 Q3	$337K	Hold	63	–	–	0.03%	242
2019 Q2	$316K	Buy	+63	New	+$3.16K	0.04%	252
2015 Q1	–	Sell	-48	Closed	-$10K	–	490
2014 Q4	$10K	Sell	48 -14	-23%	-$783	﹤0.01%	449
2014 Q3	$7K	Buy	+62	New	+$3.8K	﹤0.01%	556
2013 Q3	–	Sell	-217	Closed	-$13K	–	472
2013 Q2	$13K	Buy	+217	New	+$13.8K	0.01%	286

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Summit Securities Group's GSK Position: Q1 2026 in Review

Summit Securities Group reduced its GSK (GSK) stake by 86% in Q1 2026, selling an estimated $103K and leaving 300 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #555.

Summit Securities Group first reported a position in GSK in Q2 2013 and has held it in 36 quarters since. The position peaked at $1.97M in Q4 2019. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Summit Securities Group held 300 shares of GSK worth $16.6K as of Q1 2026.
Summit Securities Group sold 1,900 GSK shares in Q1 2026, an estimated $103K.
GSK made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #555 holding.
Summit Securities Group first reported a position in GSK in Q2 2013 and has held it in 36 quarters since.
Summit Securities Group's GSK position peaked at $1.97M in Q4 2019.
1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.